Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 2Thyroid Neoplasms 1Nasopharyngeal Neoplasms 1Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 127Gemcitabine 71Radiotherapy, Intensity-Modulated 61toripalimab 39Capecitabine 37Docetaxel 36Fluorouracil 35Radiotherapy 24camrelizumab 23Drug Therapy 22nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11tislelizumab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiation 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × penpulimab × Head & Neck × Clear all
NCT05563480 2026-04-07

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
47 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Akeso

Phase 3 Active not recruiting
296 enrolled 1 FDA
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡